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Abstract  
Introduction: Migraine is a frequent chief complaint of patients in the emergency department. A wide range 
of treatments are used for acute migraine.  
Objective: This study aimed to compare the therapeutic effects of a combination of metoclopramide + 
dexamethasone with those of ketorolac for treatment of acute migraine in the emergency department.  
Method: This quasi-experimental study enrolled patients identified as migraine headache cases admitted to 
the emergency departments of Shohadaye Tajrish and Sina hospitals, Tehran, Iran. The patients were divided 
into two groups and treated with either 8 mg Dexamethasone + 10 mg Metoclopramide or 60 mg ketorolac, 
and then compared regarding the rate of pain control based on visual analogue scale (VAS) on arrival and 1 
and 2 hours afterward. 
Results: Overall, 86 patients were recruited, of whom 50 were male (58.1%). Their mean age was 37.6 ± 10.3 
years. Thirty-five (40.7%) were in the ketorolac group and 51 (59.3%) were in the dexamethasone + 
metoclopramide group. Treatment success was defined as a reduction of at least 3 points in pain severity in 
comparison to the admission time. One hour after administration of medications, the reported pain intensity 
was 4.7 ± 2.0 and 6.2 ± 2.3 in ketorolac group and dexamethasone + metoclopramide group, respectively. By 
the second hour, pain intensity was 3.4 ± 1.2 and 2.9 ± 1.3 in ketorolac group and dexamethasone + 
metoclopramide group, respectively. The two groups did not show a significant difference in terms of the 
reported pain at this time (p= 0.04). 
Conclusion: Based on our findings, the pain reduction time was relatively shorter for ketorolac in acute 
migraine, but the final response was identical in the two groups. 
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INTRODUCTION
Headache is a frequent complaint among patients 
presenting to the emergency department (ED), and 
migraine is one of its major causes. Migraine is a 
chronic and recurrent disease. It is 
characteristically a pulsatile and unilateral 
headache with an intensity of moderate to severe, 
and an atypical migraine attack lasts for 4 to72 
hours (1). Migraine headaches affect around 11%-
12% of the US population and about 14% of the 
Iranians. It is more common among women, and 
typically begins in adolescence (2, 3). There are 
two types of therapies namely acute management 
and prophylactic therapy (4). In addition to 
conducting the diagnostic process, it is important 
for an emergency physician to perform acute pain 
management with an available, cost effective, and 
appropriate medication. Many medications can be 
used in ED, and their difference lies in their 
availability, cost, and side effects. Some of these 
agents include acetaminophen, nonsteroidal anti-
inflammatory drugs (NSAIDs), dihydroergothamin, 
triptans, valproic acid and steroids (5). Although 
dihydroergothamin and triptans are first line 
therapies in this regard, their use is sometimes 
limited due to their cost and limited availability. 
Therefore, an effective alternative treatment is 
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needed. In developing countries like Iran, the most 
widely used agents are NSAIDS, steroids, and some 
other medications to relieve vomiting and nausea 
such as metoclopramide. It appears that the most 
common NSAID used in Iran is ketorolac. It is 
available in two forms of intramuscular (IM), and 
intravenous (IV) in all EDs, but it is relatively 
contraindicated in patients with gastrointestinal 
bleeding, ischemic heart disease, renal failure, and 
allergy to NSAIDs (6). Instead, metoclopramide and 
dexamethasone are both used in such situations 
and have some reported benefits. Dexamethasone 
is frequently used for reducing recurrent pain in 
migraine patients. Metoclopramide is available in 
almost all EDs, and is used as an abortive migraine 
pain killer, but may result in extrapyramidal side 
effects in some instances (7). The purpose of this 
study is to compare the efficacy of combination 
therapy of metoclopramide-dexamethasone with 
that of parenteral ketorolac in patients with acute 
migraine headache presenting to ED. 
METHODS 
Study design 
A multi-centered quasi-experimental study was 
conducted in 2015, in EDs of Shohaday Tajrish and 
Sina hospitals, the teaching hospitals of Shahid 
Beheshti and Tehran universities of medical 
sciences. The study protocol was approved by the 
ethics committee of Shahid Beheshti University of 
Medical Sciences (IR.SBMU.MSP.REC.1394.189). 
Written informed consent for participation in the 
study was obtained from each participant. The 
researchers fully adhered to the Declaration of 
Helsinki Principles throughout the study. 
Study population 
Patients older than 18 years presenting to the EDs 
with the chief complaint of headache were 
interviewed and recruited if they met the 
diagnostic criteria for acute migraine headache 
according to International Classification of 
Headache Disorder-3 (ICHD-3). The participants 
were evaluated for pain score and, if placed in the 
range of moderate to severe headaches, they were 
candidates for receiving an injectable drug for 
controlling the headache and were therefore 
included in the study. Patients who were affected 
with or had a history of arrhythmias, ischemic 
heart disease, peptic ulcer, obsessive disorders, 
coagulation disorder, hypertension, inflammatory 
bowel disease, renal failure, liver failure, and sleep 
disorders, as well as pregnant women were 
excluded. Participants were selected using 
convenience sampling method. Patients who 
presented to the Shohadaye Tajrish Hospital’s ED 
received ketorolac and patients who presented to 
Sina Hospital’s ED received metoclopramide + 
dexamethasone combination therapy. With a 
confidence interval level of 95% and a test power 
of 90%, considering α = 0.05, and β = 0.2, the 
sample size in each group and the total sample size 
were 35 and 70 cases, respectively. 
Intervention and Data gathering 
The statistical population consisted of two groups, 
the first group received 60 mg of ketorolac and the 
second group received 8 mg of dexamethasone + 10 
mg metoclopramide intravenously. Patients' pain 
was measured and recorded on arrival based on 
the visual analogue scale (VAS). Then, patients 
were treated with 8 mg dexamethasone + 10 mg 
metoclopramide or ketorolac depending on which 
hospital they were admitted to. In case of any 
complications such as tachycardia, hypertension, 
nausea, vomiting, injection site pain, itching, 
irritability or restlessness, drug injection was 
discontinued. After drug administration, pain 
intensity was measured again after 1 and 2 hours. 
A reduction of more than 3 points in VAS was 
considered as an appropriate response to 
treatment. There was no limitation for performing 
diagnostic evaluations due to prescribing drug. 
Moreover, if the patient’s pain was not relieved by 
these drugs, a second-line drug (opioid) would be 
used for patients as rescue medicine. 
Statistical analysis 
Patient’s demographic data and the previously 
mentioned variables were imported to IBM®-
SPSS®-Statistics-V22.0 software for further 
analysis. Descriptive statistics including mean, 
frequency, percentage, and standard deviation 
(SD) were used to characterize the study 
population. The two groups were compared with t-
test and ANOVA. Depending on the type of 
response, and the results of the normality test, the 
statistical tests of variance analysis and 
independent t-tests were used. In each treatment 
group, the mean pain scores were compared at 
different times with paired t-test and Bonferroni 
correction for multiple comparisons. P-value less 
than 0.05 was considered significant. 
RESULTS 
Baseline characteristics 
Overall, 86 patients were enrolled, and 50 cases 
were male (58.1%). Their mean age was 37.6±10.3 
years with range of 19-77 years. Of the 
participants, 35 (40.7%) were in the group treated 
with ketorolac and 51 (59.3%) were treated with 
dexamethasone + metoclopramide. The mean and 
standard deviation of the age was 36.7 ± 10.1 years 
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in the patients treated with ketorolac and 
38.3±10.5 years in the patients treated with 
combination therapy of metoclopramide-
dexamethasone (p=0.49). Error! Reference 
source not found. shows the age distribution of 
the two groups. In the beginning, the severity of 
perceived pain was 8.3 ± 1.6 in the ketorolac group, 
and 8.4 ± 3.1 in the combined treatment with 
dexamethasone + metoclopramide group. At this 
time, there was no significant difference in pain 
intensity between the two groups (p = 0.78).  
Assessed pain intensity 
Error! Reference source not found. shows the 
pain intensity of the two groups during the study 
period. One hour after medication administration, 
the reported pain intensity was 4.7 ± 2.0 in the 
ketorolac group, which decreased significantly 
more than that in the dexamethasone and 
metoclopramide group (6.2 ± 2.3). In other words, 
the pain reported at the first hour after drug 
administration in the ketorolac group was less than 
that in the dexamethasone + metoclopramide 
group (p = 0.003). Two hours later, the pain score 
was 3.4 ± 1.2 in the patients in the ketorolac group 
and 2.9 ± 1.3 in the dexamethasone + 
metoclopramide group, with no statistically 
significant difference between them (p = 0.40). 
The treatment success rate 
In this study, treatment success was defined as a 
reduction of at least 3 points in pain severity in 
comparison to the time of onset. Accordingly, 
treatment success at the first hour after 
administration of drugs was 74.3% in the ketorolac 
group and 39.2% in the dexamethasone + 
metoclopramide group. At the second hour, 
treatment success rate was 85.7% in ketorolac 
group and 84.3% in the dexamethasone + 
metoclopramide group. It is worth noting that the 
pain score in 5 patients (14.3%) from the ketorolac 
group, and 8 patients (15.7%) from the 
dexamethasone + metoclopramide group had 
decreased less than 3 points after 2 hours. 
DISCUSSION 
This study assessed and compared the success rate 
of IV combination therapy using metoclopramide + 
dexamethasone with that of ketorolac therapy in 
acute migraine headaches. Although the pain 
response to the IV ketorolac was better one hour 
after treatment, finally, there was no significant 
difference in treatment success between the two 
therapies in the EDs. 
A systematic review study supplied a modified 
classification of evidence for pharmacological 
therapies for acute migraine treatment, and 
showed that both ketorolac and metoclopramide 
are level B and probably effective for acute 
migraine (supported by 1 Class I study or 2 Class II 
studies), and that steroids are level C and possibly 
effective for acute migraine (supported by 1 Class 
II study or 2 Class III studies). Based on this 
systematic review, both metoclopramide and 
ketorolac have identical therapeutic effects (8). 
A meta-analysis and systematic review study 
investigated the effect of adjunctive 
dexamethasone along with standard treatment of 
migraine, and demonstrated that combination of 
dexamethasone with standard therapy for 
migraine caused a reduction in the rate of patients 
with moderate or severe headache 24 to 72 hours 
after ED evaluation (RR = 0.87, 95% CI = 0.80 to 
0.95; absolute risk reduction = 9.7%), publication 
and selection bias occur in these types of studies 
and are known limitations (9). A randomized 
clinical trial study compared intravenous 
dexamethasone and placebo as adjunctive 
therapies in decreasing the recurrence rate of acute 
migraine headache. Overall, 115 patients were 
included in the study, and 16 patients were missed 
to follow-up. On the 3rd day of follow-up, 35% (95% 
CI 24%-48%) of the dexamethasone group and 
45% (95% CI 31%-60%) of the placebo group had 
recurrence of headache (p=0.68). This study 
showed that dexamethasone does not decrease the 
 
Figure 1: Age distribution of the patients in the two groups. 
 
 
Figure 2: The pain intensity of the two groups throughout 
the study period. 
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recurrence of headache as an adjunctive therapy 
(10). A few randomized clinical trials 
demonstrated that metoclopramide has a 
significant therapeutic efficacy in acute migraine 
headache treatment. Among limitations of these 
studies are their sample size, failure to report 
inclusion and exclusion criteria, and failure to 
report adverse effects (11-13). A randomized 
double-blind clinical trial compared 
metoclopramide with sumatriptan in ED. At the 
second hour of treatment, pain-free rates were 
59% in the metoclopramide arm and 35% in the 
sumatriptan arm (95% CI for difference of 24%: 2 
to 46%). Finally, this study expressed that 
metoclopramide may be an acceptable therapy for 
acute migraine headache in ED (11). Another study 
compared combination therapy of metoclopramide 
+ diphenhydramine with ketorolac and 
demonstrated that parenteral metoclopramide + 
diphenhydramine is more effective than ketorolac 
for acute migraine (14). In another study, Friedman 
et al. performed a randomized trial and showed 
that metoclopramide is more efficient than 
ketorolac or valproate sodium (15). A randomized 
double-blind dose-finding clinical study compared 
different dosages of metoclopramide for treating 
acute migraine. In this study, treatment with 10, 20, 
or 40 mg of metoclopramide was randomly 
assigned to patients and pain intensity was 
compared among the groups. An hour later, pain 
had improved by a mean of 4.7 numeric rating scale 
points in those who had received 10 mg (95% 
confidence interval [CI] 4.2 to 5.2 points); those 
who received 20 mg had improved by 4.9 points 
(95% CI 4.4 to 5.4 points), and those who received 
40 mg had improved by 5.3 points (95% CI 4.8 to 
5.9 points. Finally, the study showed that 20 and 40 
mg of metoclopramide had no significant 
differences with 10 mg dosage (16). A meta-
analysis and systematic review recommend using 
dexamethasone as a useful therapy for preventing 
headache recurrence and a safe adjunctive therapy 
to standard treatment for management of 
acute migraine headache in ED (17). Similarly, a 
meta-analysis of randomized clinical trials stated 
that adjunctive parenteral dexamethasone is 
associated with relief of headache recurrence in 
acute migraine (18). A study compared the efficacy 
of combined therapy of metoclopramide plus 
dexamethasone with magnesium sulfate. In this 
study, 70 patients with complaint of migraine 
headache were assessed in two groups. Those who 
received combination therapy had a reduction in 
pain intensity from 8 to 7.4 (20 minutes) (p=0.36), 
to 6.0 (1 hour), and 2.5 (2 hours) (p< 
0.0001).  Additionally, those taking magnesium 
sulfate experienced pain reduction from 8 to 5.2 
(20 minutes), 2.3 (1 hour), and 1.3 (2 hours) (p< 
0.0001). The study demonstrated that magnesium 
sulfate is more useful than combined therapy with 
metoclopramide and dexamethasone for acute 
migraine (19). Based on existing literature, it 
appears that metoclopramide and ketorolac have 
identical therapeutic effects in acute migraine 
headache, and that dexamethasone has a possible 
effect on decreasing the recurrence of headache. 
Studies on combined metoclopramide + 
dexamethasone therapy in acute migraine are few 
and further investigation is needed in this area.  
Limitations 
The first limitation, frequently seen in quasi-
experimental studies, is the lack of random 
allocation to test groups. This limitation leads to 
non-equivalent test groups and consequently 
reduces the generalizability of the results. Previous 
factors and other influential factors are not taken 
into account because variables are not controlled in 
quasi-experimental studies and their effects on 
treatment may be missed. Another limitation is the 
sampling; results obtained via convenience 
sampling cannot be generalized to the population, 
and have insufficient power in detecting 
differences among socio-demographic subgroups. 
In addition, patients were discharged from ED after 
pain relief and were not followed for recurrence or 
late side effects, and the recurrence of headache 
was not compared between the two groups. There 
was no standard regimen to compare the two types 
of therapy with. Additionally, adverse effects of the 
two therapies were not reported. 
CONCLUSIONS 
Based on the findings of this study, the pain 
reduction time was relatively shorter in the 
ketorolac group, but the final response was 
identical in the two groups. 
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